Sarah Allison Milgrom

Sarah Allison Milgrom

Auto-generated profile, based on publicly available information

Sarah Allison Milgrom

Department of Radiation Oncology, University of Colorado, Aurora, Colorado

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in Blood
Verified
Journal Article
Closed access
PDF file
MBMichael S. Binkley
Michael S. Binkley
MRM. Shahzad Rauf
M. Shahzad Rauf
SMSarah A. Milgrom
Sarah A. Milgrom
CPChelsea C. Pinnix
Chelsea C. Pinnix
RTRichard W Tsang
Richard W Tsang
RHRichard T. Hoppe
Richard T. Hoppe
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon histologic variant, and the optimal treatment for stage I-II NLPHL is undefined. We conducted a multi­center retrospective study including patients ≥16 years with stage I-II NLPHL diagnosed from 1995­2018 receiving all forms of management including radiotherapy (RT), combined modality therapy (CMT=RT+chemotherapy), chemotherapy (CT), observation after excision, rituximab and RT, and single agent rituximab (R). End points were progression­free survival (PFS), freedom from transformation, and overall survival (OS) without statistical comparison between management groups. We identified 559 patients with median age 39 years, 72.3% being male, and 54.9% having stage I disease. Median follow up was 5.5 years (IQR=3.1-10.1). 5-year PFS and OS for the entire cohort were 87.1% (95%CI=83.6-90.0%) and 98.3% (95%CI=96.4-99.2%), respectively. Primary management was RT alone (n=257, 46.0%), CMT (n=184, 32.9%), CT alone (n=47, 8.4%), observation (n=37, 6.6%), rituximab and RT (n=19, 3.4%), and rituximab alone (n=15, 2.7%). 5-year PFS rates were 91.1% (95%CI=85.3-94.7%) after RT, 90.5% (95%CI=84.8-94.1%) after CMT, 77.8% (95%CI=61.3-88.0%) after chemotherapy, 73.5% (95%CI=50.6-87.0%) after observation, 80.8% (95%CI=41.0-95.1%) after rituximab and RT, and 38.5% (95%CI=14.0-62.8%) after rituximab alone. For the RT cohort but not the CMT cohort, variant immunoarchitectural pattern and number of sites>2 were associated with worse PFS (P2 (P=0.0006). OS for patients with stage I-II NLPHLwas excellent following all managements.

21 December 2017 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
JRJay Reddy
Jay Reddy
MHMike Hernandez
Mike Hernandez
JGJillian R. Gunther
Jillian R. Gunther
BDBouthaina S. Dabaja
Bouthaina S. Dabaja
GMGeoffrey V. Martin
Geoffrey V. Martin
MFMichelle A. Fanale
Michelle A. Fanale
Summary: To determine whether pre‐treatment neutrophil/lymphocyte (NLR) or platelet/lymphocyte ratios (PLR) are predictive for progression in early‐stage classical Hodgkin lymphoma (cHL), we derived NLR and PLR values for 338 stage I/II cHL patients and appropriate cut‐off point values to define progression. Two‐year freedom from progression (FFP) for patients with NLR ≥6·4 was 82·2% vs. 95·7% with NLR <6·4 (P < 0·001). Similarly, 2‐year FFP was 84·3% for patients with PLR ≥266·2 vs. 96·1% with PLR <266·2 (P = 0·003). On univariate analysis, both NLR and PLR were significantly associated with worse FFP (P = 0·001). On multivariate analysis, PLR remained a significant, independent prognostic factor (P < 0·001).

1 January 2019 in Journal of Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
SMSarah A. Milgrom
Sarah A. Milgrom
BVBibin Varghese
Bibin Varghese
GGGregory W. Gladish
Gregory W. Gladish
ACAndrew D. Choi
Andrew D. Choi
WDWenli Dong
Wenli Dong
JLJuan C. Lopez-Mattei
Juan C. Lopez-Mattei
Milgrom SA, et al. J Cardiovasc Imaging. 2019 Apr;27:e38. https://doi.org/10.4250/jcvi.2019.27.e38

1 June 2024 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SMSarah A. Milgrom
Sarah A. Milgrom
PLPeter van Luijk
Peter van Luijk
RPRamiro Pino
Ramiro Pino
CRCecile M. Ronckers
Cecile M. Ronckers
LKLeontien C. Kremer
Leontien C. Kremer
APArnold C. Paulino
Arnold C. Paulino

3 May 2017 in Current Hematologic Malignancy Reports
Verified
Journal Article
Closed access
PDF file
CPChelsea C Pinnix
Chelsea C Pinnix
TATherese Y. Andraos
Therese Y. Andraos
SMSarah Milgrom
Sarah Milgrom
MFMichelle A. Fanale
Michelle A. Fanale

10 July 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SMSarah A. Milgrom
Sarah A. Milgrom
JKJihyun Kim
Jihyun Kim
ACAlin Chirindel
Alin Chirindel
JKJongho Kim
Jongho Kim
QPQinglin Pei
Qinglin Pei
SCSteve Y. Cho
Steve Y. Cho